LUMICKS

Status
Current portfolio
Investment type
Growth Equity
Investment date
April 2021
Location
Amsterdam, Netherlands

Founded in 2014 as an academic spinoff from VU University of Amsterdam, LUMICKS is a leading life science tools company that develops equipment for Dynamic Single-Molecule and Cell Avidity analysis, two rapidly emerging areas in biology research and immuno-oncology. Built upon innovative technologies, such as optical tweezers (Nobel Prize for Physics 2018) and STED super-resolution (Nobel Prize for Chemistry 2014), LUMICKS’ tools facilitate the understanding of life to the smallest detail.

Applying and measuring forces and interactions in biology enables real-time analysis of underlying biological mechanisms, building the crucial and yet unfinished bridge between structure and function at the molecular and cellular levels. Using LUMICKS’ groundbreaking C-Trap® Optical Tweezers – Fluorescence Microscopy, scientists are able to analyze complex biological processes in real-time. The z-Movi® Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells. Since its release in 2020, the z-Movi has been adopted by leading biotech and pharmaceutical companies around the world to accelerate the entry of cell therapies into clinical trials.

As the z-Movi platform ramps and C-Trap uptake in the translational research setting grows, LUMICKS is poised to have a measurable impact on the speed-to-market and success rate of a multitude of new therapeutics that treat a range of common and devastating diseases like cancer, infection, and autoimmune disorders.

Lauxera is exceptional in its entrepreneurial approach as an investor for our business, always available, always responsive and providing meaningful and real support on an ongoing basis.

Hugo de WitCEO at LUMICKS

We believe LUMICKS’ z-Movi Cell Avidity Analyzer for direct, high-resolution measurement of cell avidity is a revolutionary platform that can accelerate translational R&D across institutions and biopharma. The z-Movi solution has the potential to drive remarkable advances in cancer treatment. It builds on LUMICKS’ tradition of innovation, anchored by its Dynamic Single-Molecule franchise that is expanding access to and use cases for single molecule force measurement.

Alex SlackCo-founding Partner at Lauxera
Acandis

Acandis

Neurovascular medical devices — Lauxera Growth II
Antaros Medical

Antaros Medical

Imaging drug development — Lauxera Growth II
BioLamina

BioLamina

Regenerative medicine tools — Lauxera Growth I
Caresyntax

Caresyntax

Surgical intelligence platform — Lauxera Growth I
Lifen

Lifen

Digital health integration — Lauxera Growth I
Matrix One

Matrix One

Medtech compliance platform — Lauxera Growth I
Natural Cycles

Natural Cycles

Non-hormonal contraception — Lauxera Growth I
OrganOx

OrganOx

Liver transplant optimization — Lauxera Growth I
Ospi

Ospi

Healthtech data intelligence — Lauxera Growth I
Reapplix

Reapplix

Advanced wound care — Lauxera Growth I
Synovo Group

Synovo Group

Patient transportation software — Lauxera Growth I
Veranex

Veranex

Medtech innovation services — Lauxera Growth I
Verdot

Verdot

Bioprocess purification platforms — Lauxera Growth I